FY2027 Earnings Forecast for Q32 Bio Issued By HC Wainwright

Key Points

• HC Wainwright raised its FY2027 EPS forecast for Q32 Bio to a loss of $1.54 per share from a previous estimate of $2.00, while maintaining a “Buy” rating and $36 price target.
• Analyst sentiment is broadly positive, with MarketBeat reporting a “Moderate Buy” consensus rating and an average price target of $30.60; recent coverage includes “strong buy,” “overweight,” and “outperform” ratings.
• Q32 Bio shares opened at $8.25, well below their 12-month high of $23.57. The company recently reported a quarterly loss of $0.44 per share, narrowly beating the consensus estimate of a $0.46 loss.

Q32 Bio Inc. (NASDAQ:QTTB - Free Report) - Equities research analysts at HC Wainwright upped their FY2027 earnings per share (EPS) estimates for Q32 Bio in a note issued to investors on Wednesday, September 30th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($1.54) for the year, up from their previous forecast of ($2.00). HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Q32 Bio's current full-year earnings is ($1.54) per share.

A number of other research analysts have also weighed in on the stock. Mizuho raised shares of Q32 Bio to a "strong-buy" rating in a research note on Monday, September 7th. Cantor Fitzgerald restated an "overweight" rating on shares of Q32 Bio in a report on Wednesday, September 16th. Oppenheimer restated an "outperform" rating on shares of Q32 Bio in a report on Thursday. Weiss Ratings raised shares of Q32 Bio from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, August 21st. Finally, Morgan Stanley began coverage on Q32 Bio in a research note on Monday, August 24th. They set an "overweight" rating and a $34.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and two have assigned a Hold rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $30.60.

Q32 Bio Trading Down 0.2%

NASDAQ QTTB opened at $8.25 on Friday. The company has a market cap of $245.60 million, a P/E ratio of 2.75 and a beta of 0.31. The company has a fifty day simple moving average of $13.40 and a 200 day simple moving average of $10.79. Q32 Bio has a 12-month low of $1.90 and a 12-month high of $23.57.

Q32 Bio (NASDAQ:QTTB - Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported ($0.44) earnings per share for the quarter, topping analysts' consensus estimates of ($0.46) by $0.02.

Insiders Place Their Bets

In other news, CEO Jodie Morrison sold 9,845 shares of the business's stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $16.56, for a total value of $163,033.20. Following the transaction, the chief executive officer owned 343,259 shares in the company, valued at $5,684,369.04. The trade was a 2.79% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Shelia Violette sold 2,798 shares of the company's stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $16.56, for a total value of $46,334.88. Following the completion of the transaction, the insider directly owned 127,771 shares of the company's stock, valued at approximately $2,115,887.76. This represents a 2.14% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 16,615 shares of company stock valued at $275,144 in the last 90 days. 34.46% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Q32 Bio

A number of hedge funds have recently made changes to their positions in QTTB. Squarepoint Ops LLC bought a new position in Q32 Bio in the 2nd quarter worth approximately $303,000. Atlas Venture Life Science Advisors LLC boosted its holdings in shares of Q32 Bio by 29.9% in the second quarter. Atlas Venture Life Science Advisors LLC now owns 2,717,106 shares of the company's stock worth $34,616,000 after acquiring an additional 625,000 shares during the period. Susquehanna International Group LLP bought a new position in shares of Q32 Bio in the second quarter worth $297,000. Carlyle Group Inc. purchased a new position in shares of Q32 Bio in the second quarter valued at $769,000. Finally, BlackRock Inc. bought a new stake in shares of Q32 Bio during the 2nd quarter valued at $1,510,000. 31.32% of the stock is currently owned by institutional investors.

About Q32 Bio

Q32 Bio Inc is a clinical-stage biotechnology company focused on developing therapies for diseases associated with immune dysregulation. The company's research is aimed at restoring balance in the immune system by targeting biological pathways involved in inflammation, tissue repair and immune regulation.

Q32 Bio's lead product candidate is bempikibart, also known as ADX-914, a fully human monoclonal antibody designed to inhibit activin A signaling through the activin receptor type IIB pathway.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.